- Home
- OMER vs RCKT Comparison
OMER vs RCKT Comparison
Compare OMER & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- RCKT
- Stock Information
- Founded
- OMER 1994
- RCKT 1999
- Country
- OMER United States
- RCKT United States
- Employees
- OMER N/A
- RCKT N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- OMER Health Care
- RCKT Health Care
- Exchange
- OMER Nasdaq
- RCKT Nasdaq
- Market Cap
- OMER 397.1M
- RCKT 326.4M
- IPO Year
- OMER 2009
- RCKT N/A
- Fundamental
- Price
- OMER $3.21
- RCKT $2.70
- Analyst Decision
- OMER Strong Buy
- RCKT Buy
- Analyst Count
- OMER 5
- RCKT 13
- Target Price
- OMER $18.00
- RCKT $18.50
- AVG Volume (30 Days)
- OMER 808.8K
- RCKT 8.4M
- Earning Date
- OMER 08-06-2025
- RCKT 08-04-2025
- Dividend Yield
- OMER N/A
- RCKT N/A
- EPS Growth
- OMER N/A
- RCKT N/A
- EPS
- OMER N/A
- RCKT N/A
- Revenue
- OMER N/A
- RCKT N/A
- Revenue This Year
- OMER N/A
- RCKT N/A
- Revenue Next Year
- OMER $468.75
- RCKT N/A
- P/E Ratio
- OMER N/A
- RCKT N/A
- Revenue Growth
- OMER N/A
- RCKT N/A
- 52 Week Low
- OMER $2.97
- RCKT $2.19
- 52 Week High
- OMER $13.60
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- OMER 34.64
- RCKT 32.09
- Support Level
- OMER $2.97
- RCKT $2.66
- Resistance Level
- OMER $4.06
- RCKT $3.33
- Average True Range (ATR)
- OMER 0.26
- RCKT 0.28
- MACD
- OMER 0.10
- RCKT 0.09
- Stochastic Oscillator
- OMER 22.02
- RCKT 26.59
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.